ArticleTransplantation2026
Mitogen-activated Protein Kinase big Mitogen-activated Kinase-1 Mediates Protection in Liver Ischemia/Reperfusion Injury.
Article in Transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundHepatic ischemia/reperfusion injury (IRI) is a major complication occurring in hemorrhagic shock, liver resection, and transplantation. Big mitogen-activated kinase-1 (BMK1), a member of the mitogen-activated protein kinases family, is essential for regulating endothelial cell integrity and organ development.
methodsWe explored the putative role of BMK1 in human liver transplant recipients and in a murine model of partial warm liver IRI.
resultsLiver biopsies from adult transplant patients (n = 60) revealed that increased intrahepatic BMK1 expression was associated with well-preserved histology and improved graft function. In mice, the ischemia insult (90 min) induced hepatocellular BMK1 expression, peaking at 6 h of reperfusion. Inhibiting intrahepatic BMK1 (siRNA/chemically) made livers more vulnerable to IR stress, as evidenced by elevated serum alanine aminotransferase levels, damaged hepatic architecture, increased necrosis, and inflammation. Conversely, BMK1-overexpression protected livers from IR stress in a Krüppel-like factor 4 (KLF4)-dependent manner. Further in vivo and in vitro experiments confirmed that BMK1 overexpression upregulated hepatic yes-associated protein (YAP) mRNA/protein levels and promoted YAP dephosphorylation, whereas YAP silencing abrogated the protective effects of BMK1. The hypoxia-reoxygenation in vitro assay indicated that hepatocellular BMK1 regulated YAP function via itchy E3 ubiquitin protein ligase-related ubiquitination to large tumor suppressor homolog 1. Hypoxia-reoxygenation stress in BMK1-overexpressed hepatocytes resulted in increased intracellular itchy E3 ubiquitin protein ligase and decreased phosphorylated large tumor suppressor homolog 1, whereas no change in the phosphorylation level of mammalian sterile 20-like protein kinase-1. Furthermore, dual hepatocyte immunofluorescence staining revealed that BMK1 relied on the nuclear YAP-KLF4 cooperation, as hepatic deficiency of either BMK1, YAP, or KLF4 enhanced the severity of hepatic IRI.
conclusionsThis study documents the crucial role/underlying mechanism of BMK1 signaling and points to a novel target to minimize hepatocellular dysfunction in IR-stressed liver transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.